Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has issued an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced the schedule for its 2024 Annual General Meeting (AGM), set to take place on May 22, 2025, in Shenzhen, China. The AGM will address several key resolutions, including the approval of the 2024 Work Reports, Annual Report, Profit Distribution Proposal, and amendments to the Share Incentive Schemes. Additionally, special resolutions will cover the re-appointment of auditors, purchase of wealth management products, and application for credit lines. These resolutions are crucial for the company’s strategic planning and financial management, potentially impacting its operational efficiency and stakeholder relations.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the production and sale of heparin products. The company operates within the pharmaceutical industry and focuses on providing high-quality pharmaceutical products to the global market.
YTD Price Performance: 9.34%
Average Trading Volume: 3,875,594
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.32B
See more insights into 9989 stock on TipRanks’ Stock Analysis page.